Patent Application
20150065708
The present invention belongs to the field of heterocyclic compound (C07D), wherein, the heterocyclic compound contains two or more heterocyclic rings, and nitrogen is the only heterocyclic atomin the same cyclic system, including at least a hexatomic ring with at least one nitrogen atom (471/00). In particular, the present invention relates to a compound [4-(2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-glutamate, as well as its crystal form, preparation method and applications.
The compound with triazabicyclo[3.2.1]octane structure has attracted great attention of chemists and medical experts because of its unique molecular structure. Aplaminal is the first compound that is found to have triazabicyclo[3.2.1
octane structure, and was first separated by Takeshi Kuroda and Hideo Kigoshi et al. from Aplysia (Varria) kurodaiin 2008 (Org. Lett., Vol. 10, No. 3, p489-491, 2008). Its specific structure is as follows:
The literature characterizes the structure of Aplaminal through NMR and single crystal X-ray diffraction. It is reported that Aplaminal has the cytotoxicity against HeLa S3 cells (IC50=0.51 ug/mL). More clinical trials of it are still under study.
The preparation of Aplaminal through biological extraction involves extremely high cost and very low yield, and only 2 mg of Aplaminal can be extracted from 18 kg of aplysia. Therefore, Amos B. Smith III and Zhuqing Liu et al. (Org. Lett., Vol. 10, No. 19, p4363-4365, 2008) prepared Aplaminal through synthesis with N-Boc-(D)-serine as the raw material in 9 reaction processes, such as the hydroxyl protection, condensation, reduction, etc., with the yield of 17%. The specific reaction process is as follows:
But it is also very difficult to synthesize the compound with triazabicyclo[3.2.1]octane structure. The above synthetic method of Aplaminal suffers from redundant reaction process, expensive reagents such as diisobutylaluminum hydride (Dibal-H), Pd and Pt, difficult pilot process control, less safety and low yield, and is also not applicable for industrial production. At present, there are many reports on other triazacyclo compounds. The patent document CN1864663 discloses the pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene. The patent document CN102282148A discloses 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]hept acosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt. The patent document CN1509288 discloses the citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene. The patent document CN1509174 discloses the tartrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene. The patent document CN1589148 discloses the succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0.2, 10.04,8]-hexadeca-2(11),3,5,7,9-pentaeneandpharmaceutica 1 compositions thereof. These patent documents all disclose such a chemical structure with triazatetracyclo.
Through careful researches, the inventor has unexpectedly developed a simple, feasible and economic method of successfully preparing a novel compound with triazabicyclo[3.2.1]octane structure with 5-methyltetrahydrofolate as the raw material. This compound has significant effect on inhibiting T lymphocyte proliferation.
The first object of the present invention is to provide a novel compound with triazabicyclo[3.2.1]octane structure, and characterize its structure. Its chemical name is [4-(2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4-a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-glutamate, hereinafter referred to as JK12A.
The second object of the present invention is to provide a crystal form of the above compound JK12A.
The third object of the present invention is to provide a preparation method of the above compound JK12A.
The fourth object of the present invention is to provide applications of the above compound JK12A.
Therefore, the present invention proposes the compound JK12A with the following structural formula:
or a stereomer of the compound JK12A.
The present invention proposes the crystal of the compound JK12A.
The present invention proposes a pharmaceutically acceptable salt of the compound JK12A or a stereomer of the salt, wherein the salt is a crystallized salt.
The present invention also provides the X-ray diffraction pattern of the crystal form I of the compound JK12A with Cu-Ka radiation, and with diffraction peaks at 2θangle expressed in terms of degrees at 13.3±0.2, 14.0±0.2, 16.9±0.2, 19.1±0.2, 24.4±0.2 and 27.6±0.2.
Furthermore, the present invention also provides the X-ray diffraction pattern of the crystal form I of the compound JK12A with Cu-Ka radiation, and with diffraction peaks at 2θangle expressed in terms of degrees at 13.3, 14.0, 16.9, 19.1, 24.4 and 27.6. The further X-ray diffraction pattern of the crystal form I of the compound JK12A is practically as shown in
The present invention also provides the X-ray diffraction pattern of the crystal form II of the compound JK12A with Cu-Ka radiation, and with diffraction peaks at 2θangle expressed in terms of degrees at 6.8±0.2, 12.2±0.2, 13.7±0.2, 15.9±0.2, 18.4±0.2 and 23.0±0.2.
Furthermore, the present invention also provides the X-ray diffraction pattern of the crystal form II of the compound JK12A with Cu-Ka radiation, and with diffraction peaks at 2θangle expressed in terms of degrees at 6.8, 12.2, 13.7, 15.9, 18.4 and 23.0. The further X-ray diffraction pattern of the crystal form II of the compound JK12A is practically as shown in
The present invention provides a preparation method of the compound JK12A, comprising the process of oxidizing 5-methyltetrahydrofolate.
The present invention provides a preparation method of the crystal form I of the compound JK12A, comprising the following steps:
a) Adding the 5-methyltetrahydrofolate into polar medium;
b) Regulating the pH with alkali to 6-8;
c) Adding an oxidizing agent with stirring;
d) Regulating the pH with acid to 3-5;
The present invention also provides a preparation method of the crystal form II of the compound JK12A, comprising crystallization of the compound JK12A in polar medium through ultrasonication at pH≧3. The polar medium is water or a mixture of water and a polar water-soluble organic solvent.
Furthermore, the present invention provides a preparation method of the crystal form II of the compound JK12A, comprising the following steps:
a) Adding the compound JK12A into polar medium;
b) Regulating the pH with alkali to 6˜10, until the solid is dissolved;
c) Crystallization through ultrasonication and regulating the pH with acid to 3˜6.
Purity of the crystal form I and II of the compound JK12A prepared from the above method can reach above 98.0%.
The present invention also provides a method for converting the compound JK12A to 5-methyltetrahydrofolate by reducing the compound JK12A to 5-methyltetrahydrofolate.
The present invention also provides a method for converting the compound JK12A to 5-methyltetrahydrofolate. An embodiment of the conversion method is to dissolve the compound JK12A in water in the presence of alkali, then react with a reducing agent, and finally obtain 5-methyltetrahydrofolate.
The present invention also provides applications of the compound JK12A to preparing drugs as an active ingredient for medicament or food additives.
In order to better understand the technical scheme of the present invention, the detailed description of the invention below is used to further illustrate the technical scheme of the present invention, but is not intended to restrict the present invention.
The compound JK12A referred to in the present invention can be characterized by various means.
The compound JK12A, being synthesized through oxidation of 5-methyltetrahydrofolate. Where, chemical name of the 5-methyltetrahydrofolate is N-[4-[[(2-amino-1,4,5,6,7,8,-hexahydro-4-oxo-5-methyl-6-pteridinyl)methyl]amino]benzoyl]-L-glutamate. Please see the patent documents CN1122337A, CN92100247.5, CN200910134474.4, CN200610041541.4, CN00108884.X and GR3029552T3 for the characteristics of 5-methyltetrahydrofolate, therefore the technical disclosures of each of which is incorporated herein by reference in its entirety.
In the invention, 5-methyltetrahydrofolateisoxidized with an oxidizing agent. As described below, the oxidizing agent may be air, or oxygen, or hydrogen peroxide.
The compound JK12A, being prepared with the following method:
a) Dissolving 5-methyltetrahydrofolate in polar medium in the presence of alkali;
b) Generating the compound JK12A through reaction with the oxidizing agent;
c) Separating the compound JK12A from solution with acid.
Where, nitrogen or inert gas protection may be used in the step a); nitrogen is preferred; 5-methyltetrahydrofolate solution is regulated with alkali to pH value of 6˜8, until the solid is dissolved. In the step b), high active surfactant may be used as a catalyst and/or ultrasonication may be used; the oxidizing agent is preferably air, or oxygen, or hydrogen peroxide. In the step c), the reaction solution is regulated to pH 3˜5 preferably with acid. After precipitation, the solid is filtered, washed and dried. The preparation process is carried out under normal pressure and at normal temperature. The technical personnel in this field determine the duration of each step according to the use level of the raw material (5-methyltetrahydrofolate), alkali and acid, etc.
The compound JK12A, also having the molecular structure as follows:
The present invention also relates to a variety of stereomers of the compound JK12A, such as [4-((4aS,7R)-2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4-a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-L-glutamate, [4-((4aS, 7S)-2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-L-glutamate, [4-((4aR, 7S)-2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-L-glutamate, [4-((4aR, 7R)-2-amino-10-methyl-4-oxo-6,7,8,9-tetrahydro-4-a,7-cycloimino-pyrimido[4,5-b][1,4]diazepine-5(4H)-yl)benzoyl]-L-glutamate, etc.
JK12A in the present invention may be characterized by any one or more of the following means:
The present invention also relates to the crystal of the compound JK12A. Through experiment, the inventor found two crystal forms.
The preparation method of the crystal form I of the compound JK12A crystal, comprising the following steps:
a) Adding the 5-methyltetrahydrofolate into polar medium;
b) Regulating the pH with alkali to 6-8;
c) Adding an oxidizing agent with stirring;
d) Regulating the pH with acid to 3-5;
Preferably, in the step a), the polar medium is water or a mixture of water and a water-miscible organic solvent. This method does not have specific requirements for the use level of the polar medium, preferably the general use level of reaction or crystallization medium. The 5-methyltetrahydrofolate is selected from (6S)-5-methyltetrahydrofolate, (6R)-5-methyltetrahydrofolate and (6R, S)-5-methyltetrahydrofolate, preferably (6S)-5-methyltetrahydrofolate.
In the step b), the alkali is an organic alkali or inorganic alkali that can form a salt with 5-methyltetrahydrofolate, wherein, the inorganic alkali is selected from alkali of alkalis or alkaline earth, carbonate and bicarbonate; the organic alkali is selected from ammonia, amine, pyridine and piperazine; preferably potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, ammonia, monomethylamine, 4-dimethylpyridine, and piperazine. The alkali may be directly added, or added in the form of solution (aqueous solution for instance). pH value of the solution is regulated with alkali generally to 6.0˜8.0, preferably 7.0˜7.5.
In the step c), the oxidizing agent is air, or oxygen, or hydrogen peroxide.
Preferably, a step of adding high active surfactant before the step c) can be included. The high active surfactant is selected from active carbon, active silica gel and active aluminum oxide, preferably active carbon, where the use level of the high active surfactant is 0.05˜10 times as much as the mass of 5-methyltetrahydrofolate, preferably 0.5˜2 times, and more preferably 0.5˜1 times. More preferably, the high active surfactant is added between the step b) and step c), that is, the oxidizing agent is added immediately after adding the high active surfactant. The stirring is preferably terminated after the reaction of the raw material 5-methyltetrahydrofolate is over, as indicated by HPLC, lasting for generally more than 10 hours, and preferably 12-24 hours.
In the step d), the acid is organic acid or inorganic acid. Preferably, the inorganic acid is selected from hydrochloric acid, sulfuric acid and hydrobromic acid; the organic acid is selected from formic acid, acetic acid and phenylmethanesulfonic acid. pH value of the solution is preferably regulated with acid to 4˜5. It is understandable that after crystallization, steps such as filtration, washing, drying and the like can be carried out.
Furthermore, characteristics of the crystal form I of the compound JK12A are that the main peaks of the X-ray diffraction pattern in terms of 2θ and distance d measured through CuKα radiation (within the error range) are listed as follows:
The crystal form II of the compound JK12A, wherein, the compound JK12A is crystallized with the aid of ultrasonication in polar medium at pH≧3. Preferably, the polar medium is water or a mixture of water and a polar water-soluble organic solvent. Furthermore, the preparation method of the crystal form II of the compound JK12A, comprising the following steps:
a) Adding the compound JK12A into polar medium;
b) Regulating the pH with alkali to 6˜10, until the solid is dissolved;
c) Crystallization through ultrasonication and regulating the pH with acid to 3˜6.
In the step a), the compound JK12A may be amorphous or crystal form I. The polar medium is water or a mixture of water and a polar water-soluble organic solvent. In the step b), the alkali is organic alkali or inorganic alkali. Preferably, the inorganic alkali is selected from potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, potassium bicarbonate and sodium bicarbonate; the organic alkali is selected from ammonia, monomethylamine,4-dimethylpyridine and piperazine. The alkali may be directly added, or added in the form of solution (aqueous solution for instance). pH value of the solution is regulated with the alkali preferably to 7.0˜8.0, and more preferably 7.0˜7.5.
In the step c), the acid is organic acid or inorganic acid. Preferably, the inorganic acid is selected from hydrochloric acid, sulfuric acid and hydrobromic acid; the organic acid is selected from formic acid, acetic acid and phenylmethanesulfonic acid. pH value of the solution is preferably regulated with acid to 3˜4. In the step b), ultrasonic may be used to facilitate fast dissolution of the compound JK12A. In the step c), ultrasonic is used to facilitate formation of the crystal form II. The technical personnel in this field determine the ultrasonic duration, and may stop it after enough solid precipitates.
Furthermore, characteristics of the crystal form II of the compound JK12A are that the main peaks of the X-ray diffraction pattern in terms of 2θ and distance d measured through CuKα radiation (within the error range) are listed as follows:
The present invention also relates to a method for converting the compound JK12A to 5-methyltetrahydrofolate, comprising reducing the compound JK12A to 5-methyltetrahydrofolate. The method may also be used for purification of 5-methyltetrahydrofolate. Crude product of 5-methyltetrahydrofolate is oxidized to form JK12A, which is reduced to 5-methyltetrahydrofolate after crystallization. The 5-methyltetrahydrofolate is obtained with significantly improved chemical purity and optical purity. Therefore, one of the applications of the compound JK12A of the present invention is to prepare and purify 5-methyltetrahydrofolate.
The present invention relates to a preparation method of 5-methyltetrahydrofolate, wherein, the compound JK12A is reduced to 5-methyltetrahydrofolate.
Preferably, the preparation method of 5-methyltetrahydrofolate comprises: first dissolving the compound JK12A in water in the presence alkali, then adding the reducing agent, and obtaining 5-methyltetrahydrofolate through separation. Wherein, the reducing agent is preferably borohydride, or reducing gas, or sulfhydryl compound. The borohydride is selected from sodium borohydride, potassium borohydride and potassium tri-tert-butylborohydride; the reducing gas is selected from H2 and borane; the sulfhydryl compound is selected from mercaptoethanol, cysteine and mesna. The separation refers to separating 5-methyltetrahydrofolate from solution, is a prior art, and may be referred to in relevant reference documents cited hereinbefore.
The alkali is an inorganic alkali or organic alkali that can form a salt with 5-methyltetrahydrofolate. The inorganic alkali is selected from alkali of alkalis or alkaline earth, carbonate and bicarbonate; the organic alkali is selected from ammonia, amine, pyridine and piperazine; preferably: potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, ammonia, monomethylamine, 4-dimethylpyridine and piperazine. The alkali may be directly added, or added in the form of solution (aqueous solution for instance). The present invention also relates to an acceptable salt of the compound JK12A, which is selected from alkali metal salt or alkaline earth metal salt, preferably potassium salt, sodium salt, calcium salt, magnesium salt, barium salt and strontium salt, and more preferably calcium salt.
The present invention also relates to a preparation method of the calcium salt of the compound JK12A, comprising the following steps:
a) Adding the compound JK12A into polar medium;
b) Regulating the pH with alkali to 7˜8, until the solid is dissolved;
c) Adding calcium chloride;
d) Solid precipitation through ultrasonication, then filtration, washing and drying;
In the step a), the polar medium is water or a mixture of water and a polar water-soluble organic solvent, preferably water. In the step b), the alkali is an organic alkali or inorganic alkali. Preferably, the inorganic alkali is selected from potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, potassium bicarbonate and sodium bicarbonate; the organic alkali is selected from ammonia, monomethylamine,4-dimethylpyridine and piperazine.
The compound JK12A is used as an active ingredient of drugs in drug preparation. The immune bioactivity experiment in Example 16 shows that the compound JK12A can be used to prepare drugs, and may also be used to prepare food additives.
The pharmaceutical preparations or compositions in the present invention contain the above compound JK12A or salt thereof. The compound JK12A or salt thereof prepared with the method in the present invention is ideal for pharmaceutical preparations. The pharmaceutical preparations in the present invention may contain one or more excipients besides active ingredients. The excipients are added to pharmaceutical preparations for various purposes. The above preparations may be prepared with the prior art in this field.
The compound JK12A prepared in the present invention is analyzed as follows:
Instrument model: TU-1901, Beijing Purkinje General Instrument Co., Ltd
Sample concentration: 0.02366 mg/mL
Scan range: 200.00-900.00 nm
Scanning interval: 0.50 nm
Test result: UV spectrum of this product shows that there are maximum absorption at 203.0 nm, 252.5 nm and 295.5 nm, respectively corresponding to absorption of —C═O and K band of the benzene ring. UV absorption spectrum is shown in
Instrument model: Shimadzu, FTIR Presitage 21
Test conditions: KBr tabletting method
Test result: Main absorption peaks and corresponding groups are shown in Table 1. The IR absorption spectrum is shown in
Instrument model: Bruker Daltonics, Inc., APEX III 7.0TESLAFTMS
Test result: Elementary composition of this product is measured using the high resolution mass spectrum. 456.16376 peak is obtained through detection in the anionic mode of ESI-MS/MS, showing that elementary composition of this product is C20H23N7O6. Data list is shown in Table 2, and the mass spectrum is shown in
Instrument model: Bruker, AVANCE III500 MHz UltraShield-Plus™ digital NMR spectrometer
Test result: NMR spectrum is shown in
1H-1H COSY
1H-1H NOESY
Under nitrogen protection, 5 g of 5-methyltetrahydrofolate was dissolved in 50 g of water in a reaction flask with stirring, and then regulated with saturated sodium carbonate solution to pH 7.5. After the solid was completely dissolved, 2.5 g of active carbon was added, and then sealed in an oxygen balloon overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.8 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 3.0 g of yellow solid was obtained through vacuum drying with purity of 87.53%.
Under nitrogen protection, 5 g of 5-methyltetrahydrofolate was dissolved in 40 g of water in a reaction flask with stirring, and then regulated with 90% monomethylamine solution to pH 7.0. After the solid was completely dissolved, 2.5 g of active carbon was added, and then sealed in an oxygen balloon overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 10% hydrochloric acid to pH 3.0 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 2.5 g of yellow solid was obtained through vacuum drying with chemical purity of 97.37%.
Under nitrogen protection, 5 g of 5-methyltetrahydrofolate was dissolved in 40 g of water in a reaction flask with stirring, and then regulated with 10% sodium hydroxide solution to pH 7.5. After the solid was completely dissolved, 2.5 g of active carbon was added, and then kept open overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.2 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 2.3 g of yellow solid was obtained through vacuum drying with chemical purity of 95.00%.
Under nitrogen protection, 73.3 g of 5-methyltetrahydrofolate was dissolved in 580 g of water in a reaction flask with stirring, and then regulated with 10% sodium hydroxide solution to pH 7.2. After the solid was completely dissolved, 40 g of active carbon was added, and then sealed in an oxygen balloon overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.0 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 47.8 g of yellow solid was obtained through vacuum drying with chemical purity of 96.20%.
Under nitrogen protection, 10 g of 5-methyltetrahydrofolate was dissolved in 80 g of water in a reaction flask with stirring, and then regulated with 10% sodium hydroxide solution to pH 7.3. After the solid was completely dissolved, 5 g of active carbon was added, and then kept open overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.0 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 6.0 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 99.42%.
Under nitrogen protection, 5 g of 5-methyltetrahydrofolate was dissolved in 40 g of water in a reaction flask with stirring, and then regulated with 10% sodium hydroxide solution to pH 7.5. After the solid was completely dissolved, 5 g of active carbon was added, and then sealed in an oxygen balloon overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.8 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 2.7 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 99.60%.
Under nitrogen protection, 5 g of 5-methyltetrahydrofolate was dissolved in 50 g of water in a reaction flask with stirring, and then regulated with 10% sodium hydroxide solution to pH 7.2. After the solid was completely dissolved, 4 g of active silica gel was added, and then sealed in an oxygen balloon overnight. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 50% acetic acid to pH 4.5 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 2.3 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 98.41%.
2.0 g of JK12A was dissolved in 22 g of water in an ice water bath. 10% sodium hydroxide was added dropwise with stirring to regulate the solution to pH 6.7. After the solid was completely dissolved, the reaction solution was transferred to an ultrasonic device, and 50% acetic acid was added dropwise to regulate pH value of the solution to 5.2. 30 min later, the system was filtered, the filter cake was respectively washed with water, ethanol and acetone, and then 1.0 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 98.2%.
5.0 g of JK12A was dissolved in 50 g of water in an ice water bath. 10% sodium hydroxide was added dropwise with stirring to regulate the solution to pH 7.5. After the solid was completely dissolved, the reaction solution was transferred to an ultrasonic device, and 50% acetic acid was added dropwise to regulate pH value of the solution to 4.0. 30 min later, the system was filtered, the filter cake was respectively washed with water, ethanol and acetone, and then 2.2 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 98.5%.
8.0 g of JK12A was dissolved in 120 g of water in an ice water bath. 10% sodium hydroxide was added dropwise with stirring to regulate the solution to pH 8.0. After the solid was completely dissolved, the reaction solution was transferred to an ultrasonic device, and 50% acetic acid was added dropwise to regulate pH value of the solution to 5.0. 30 min later, the system was filtered, the filter cake was respectively washed with water, ethanol and acetone, and then 5.2 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 98.7%.
4.0 g of JK12A was dissolved in 20 g of water with stirring at room temperature. 10% sodium hydroxide was added to regulate the solution to pH 7.0. After the solid was completely dissolved, the reaction solution was cooled to 10° C. 4.0 g of 50% calcium chloride solution was added with stirring for 10 min. Then 25 mL of ethanol was added. After kept in an ultrasonic device for 30 min, the system was filtered, the filter cake was respectively washed with ethanol and acetone, and then 3.5 g of calcium salt of JK12A was obtained through vacuum drying with chemical purity of 97.6%.
3.0 g of JK12A (purity 96.64%) was dissolved in 60 g of water, and then regulated with 10% sodium hydroxide to pH 7.0 with stirring. After the solid was completely dissolved, 2 g of KBH4 was slowly added with further stirring for 1 hour. Then test showed that the content of 5-methyltetrahydrofolate was 71.26% in the reaction solution.
3 g of JK12A (purity 96.64%) was dissolved in 60 g of water, and then regulated with 10% sodium hydroxide to pH 7.2 with stirring. After the solid was completely dissolved, 2 g of NaBH4 was slowly added with further stirring for 1.5 hours. Then test showed that the content of 5-methyltetrahydrofolate was 79.32% in the reaction solution.
10 g of JK12A (purity 96.64%) was dissolved in 150 g of water, and then regulated with 10% sodium hydroxide to pH 7.0 with stirring. After the solid was completely dissolved, 1.0 g of Pd/C was added, and fully stirred. After H2 was insufflated, the system was pressurized to 0.2 MPa, and stirred for 2 h. Then test showed that the content of 5-methyltetrahydrofolate was 70.32% in the reaction solution.
10 g of 5-methyltetrahydrofolate (chemical purity 82%, optical purity 90%) was dissolved in 1000 g of water, and then regulated with 10% sodium hydroxide to pH 7.0 with stirring. After the solid was completely dissolved, 5 g of active carbon was added, and sealed in an oxygen balloon. After HPLC showed that the reaction of raw materials was completed, the system was filtered, and the filtrate was regulated with 10% hydrochloric acid to pH 3.0 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 5.2 g of yellow solid JK12A was obtained through vacuum drying with chemical purity of 97.8%. The solid was added into 80 g of water, and then regulated with 10% sodium hydroxide to pH 7.0 with stirring. 12 g of sodium borohydride was slowly added. 4 hours later, the solution was regulated with 10% hydrochloric acid to pH 3.0 for crystallization. After filtration, the filter cake was respectively washed with ethanol and acetone, and then 2.9 g of 5-methyltetrahydrofolate was obtained through vacuum drying with chemical purity of 98.1% and optical purity of 96%.
After mice were killed through spine dislocation, their spleen was taken aseptically to prepare single cell suspension. Redblood cells were removed from red blood cell lysis buffer, and the cell concentration was regulated.
Effect of the compound on the activity of murine splenic lymphocytes was detected with CCK-8 method:
Murine splenic lymphocyte suspension was inoculated in 96-well plates with 5×105/well. Meanwhile, different concentration of compound were added, corresponding solvent control and nutrient solution background control were also arranged. The total volume was 200 μL. The suspension was cultivated in an incubator with 5% CO2 at 37° C. for 48 hours. 8-10 hours before the cultivation was completed, CCK-8 solution was added. On completion of the cultivation, the OD value was measured with an ELIASA at 450 nm (reference 650 nm). Effect of the compound on the proliferation function of murine splenic lymphocytes was detected with 3H-TdR incorporation method:
Murine splenic lymphocyte suspension was inoculated in 96-well plates with 5×105/well. ConA (final concentration: 5 μg/ml) and different concentration of compound were added. Corresponding control well without ConA and control well without drugs were also arranged. The suspension was cultivated in an incubator with 5% CO2 at 37° C. for 48 hours. 8 hours before the cultivation was completed, 25 μl of 3H-TdR (10 μCi/ml) was added to each well. The suspension was further cultivated until the experiment was completed. Cells were collected with a cell collector onto a glass fiber membrane. After adding scintillation solution, the count of 3H-TdR incorporated into cellular DNA was obtained from a Beta counter (MicroBeta Trilux, PerkinElmer). The cell proliferation was expressed in terms of CPM.
According to the preliminary screening results, the compound JK12A has significant effect on inhibiting murine T lymphocyte proliferation (at 1.024 and 0.41 uM).
Instrument model: Bruker D8 advance XRD
Diffracted ray: CuKα radiation (40 kV, 40 mA)
Scan rate: 8°/min (2θvalue)
Scan range: 5°˜45° (2θ value)
PEAK: 27-pts/ParaBolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Summit
Instrument model: Bruker D8 advance XRD
Diffracted ray: CuKα radiation (40 kV, 40 mA)
Scan rate: 8°/min (2θ value)
Scan range: 5°˜45° (28 value)
PEAK: 21-pts/ParaBolic Filter, Threshold=3.0, Cutoff=0.1%, BG=3/1.0, Peak-Top=Summit
| Number | Date | Country | Kind |
|---|---|---|---|
| 201210109743.3 | Apr 2012 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2013/073959 | 4/9/2013 | WO | 00 |
